Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

889
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
889
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

849
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
849
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

219
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
219
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

247
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
247

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex differences in gastrointestinal bleeding among patients with cardiovascular diseases: A secondary analysis of the INTERBLEED study.

Thrombosis research·2026
Same author

Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial.

European heart journal·2026
Same author

Implantable Cardioverter-Defibrillator Therapy and Implantable Cardioverter-Defibrillator Complications in Idiopathic Ventricular Fibrillation Patients.

JACC. Clinical electrophysiology·2026
Same author

Cardiovascular Outcomes Following Major Gastrointestinal Bleeding in Patients With Pre-Existing Cardiovascular Disease: The INTERBLEED International Prospective Cohort Study.

Gastroenterology·2026
Same author

Self-Administered Etripamil Nasal Spray Slows Ventricular Rate in Patients With Atrial Fibrillation: A Post Hoc Analysis of the NODE-303 Study.

Journal of cardiovascular electrophysiology·2026
Same author

Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trial.

Diabetes, obesity & metabolism·2025

Related Experiment Video

Updated: Aug 24, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K

Andexanet Alfa and its Clinical Application.

Fauve A Noordergraaf1, Marco Alings1,2

  • 1Department of Cardiology, Amphia Hospital, Breda, Netherlands.

Heart International
|October 24, 2022
PubMed
Summary

Andexanet alfa is a new antidote for Factor Xa (FXa) inhibitors, offering reversal for patients with life-threatening bleeding. Proper use is crucial to prevent unnecessary administration and ensure patient safety.

Keywords:
Andexanet alfafactor Xa inhibitorsmajor bleedingreversal agent

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.0K

Related Experiment Videos

Last Updated: Aug 24, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.0K

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Factor Xa (FXa) inhibitors are crucial for preventing strokes and treating venous thromboembolism.
  • While safer than warfarin, FXa inhibitors carry bleeding risks, historically lacking a specific reversal agent.
  • The availability of andexanet alfa addresses this unmet need for FXa inhibitor reversal.

Purpose of the Study:

  • To review the mode of action, indications, and efficacy of andexanet alfa.
  • To emphasize the importance of appropriate clinical use and prevent unnecessary administration.
  • To propose a practical tool for guiding andexanet alfa's application.

Main Methods:

  • Literature review of andexanet alfa's pharmacology and clinical data.
  • Analysis of approved indications for reversal of rivaroxaban and apixaban.
  • Discussion of best practices for clinical implementation and patient selection.

Main Results:

  • Andexanet alfa is approved for reversing anticoagulation from rivaroxaban or apixaban in cases of life-threatening or uncontrolled bleeding.
  • Its use is associated with rapid reversal of FXa inhibitor activity.
  • Guidelines for appropriate use are essential to maximize benefit and minimize risk.

Conclusions:

  • Andexanet alfa provides a vital option for managing bleeding complications associated with FXa inhibitors.
  • Strict adherence to indications and protocols is necessary for safe and effective use.
  • Multidisciplinary assessment and institutional guidelines are key to preventing misuse.